Blue Cross plans are retreating from GLP-1 weight-loss drug coverage after spending hundreds of millions of dollars on the ...

Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access ...

The chief commercial officer at Form Health advises benefit managers to take a close look at vendors and employee needs to ...

Based on the findings, a majority of these employers are not covering these drugs, with only 18% confirming coverage. Larger firms are more likely to cover GLP-1 drugs, with 28% confirming coverage.

Survey data suggest that less than half of employers with 500 or more workers cover GLP-1 medications for obesity. For small employers, coverage is less likely. In response to the frequent lack of ...

Doug Long, VP, industry relations, IQVIA, discusses how soaring demand for GLP-1 therapies is driving reimbursement challenges ... On the payer side, some companies are starting to exclude coverage ...

The recent decision by some US states to cover glucagon-like peptide-1 (GLP-1) agonists for obesity treatment marks a shift ...

CVS Caremark to list Wegovy as preferred GLP-1 drug on top formularies starting July 1, 2025. Novo Nordisk plans continued collaboration with CVS to widen Wegovy access. Unlock your all-in-one ...

GLP-1 stands for glucagon-like peptide-1, a satiety hormone the body produces when we eat to help stimulate digestion and ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

The percentage of adult patients with a diagnosis of overweight or obesity increased from 10.4% in 2019 to 15.7% in 2024.

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...